London
· Delayed Price · Currency is GBP · Price in GBX4basebio Statistics
Total Valuation
4basebio has a market cap or net worth of GBP 185.68 million. The enterprise value is 192.83 million.
| Market Cap | 185.68M |
| Enterprise Value | 192.83M |
Important Dates
The next estimated earnings date is Friday, September 20, 2024.
| Earnings Date | Sep 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
4basebio has 12.81 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Shares Outstanding | 12.81M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 14.73% |
| Owned by Institutions (%) | 23.07% |
| Float | 5.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 353.03 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.16 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -27.36 |
Financial Position
The company has a current ratio of 2.21
| Current Ratio | 2.21 |
| Quick Ratio | 1.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.48 |
| Interest Coverage | -27.04 |
Financial Efficiency
Return on equity (ROE) is -231.29% and return on invested capital (ROIC) is -49.95%.
| Return on Equity (ROE) | -231.29% |
| Return on Assets (ROA) | -43.23% |
| Return on Capital (ROIC) | -49.95% |
| Revenue Per Employee | 6,024 |
| Profits Per Employee | -91,250 |
| Employee Count | 84 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +127.64% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +127.64% |
| 50-Day Moving Average | 1,459.10 |
| 200-Day Moving Average | 1,087.16 |
| Relative Strength Index (RSI) | 52.56 |
| Average Volume (20 Days) | 1,099 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4basebio had revenue of GBP 506,000 and -7.67 million in losses. Loss per share was -0.62.
| Revenue | 506,000 |
| Gross Profit | 340,000 |
| Operating Income | -8.17M |
| Pretax Income | -8.35M |
| Net Income | -7.67M |
| EBITDA | -7.60M |
| EBIT | -8.17M |
| Loss Per Share | -0.62 |
Balance Sheet
The company has 3.31 million in cash and 10.46 million in debt, giving a net cash position of -7.15 million or -0.56 per share.
| Cash & Cash Equivalents | 3.31M |
| Total Debt | 10.46M |
| Net Cash | -7.15M |
| Net Cash Per Share | -0.56 |
| Equity (Book Value) | -492,000 |
| Book Value Per Share | -0.04 |
| Working Capital | 2.75M |
Cash Flow
In the last 12 months, operating cash flow was -6.18 million and capital expenditures -871,000, giving a free cash flow of -7.05 million.
| Operating Cash Flow | -6.18M |
| Capital Expenditures | -871,000 |
| Free Cash Flow | -7.05M |
| FCF Per Share | -0.55 |
Margins
| Gross Margin | 67.19% |
| Operating Margin | -1,613.83% |
| Pretax Margin | -1,650.99% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,393.08% |
Dividends & Yields
4basebio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | -4.29% |
| FCF Yield | -3.80% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |